Virtual Library
Start Your Search
R. Pirolli
Author of
-
+
P3.03 - Poster Session/ Treatment of Locoregional Disease – NSCLC (ID 214)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Locoregional Disease – NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.03-015 - Outcomes of Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer in South of Brazil (ID 2427)
09:30 - 09:30 | Author(s): R. Pirolli
- Abstract
Background:
Patient with stage III lung cancer are commonly treated with chemotherapy and radiation. The concurrent treatment improves local control and overall survival, but also increase toxicity. A meta-analysis study with more than 1800 patients found a 30% reduction in 2-years mortality in who received a platinum-based chemotherapy. Trials populations are selected and usually are not representative of Brazil lung cancer population.
Methods:
From January 2005 to December 2013, all patients diagnosed with locally advanced non-small cell lung cancer (IIIA or IIIB) treated with etoposide/cisplatin (EP) with concurrent radiotherapy at an University Hospital in South of Brazil were identified from electronic database. Medical records were revised and demographic data, tumor and treatment characteristics were collected. Overall survival and progression freen survival were estimated by Kaplan-Meier curves. Multivariate analysis (Log-Rank tests) was performed to identify factors associated with survival. Statistical analysis was performed with SPSS 22.0.
Results:
Seventy-three patients were identified and included in analysis. Patients characteristics revealed a mean age of 59.2 ± 10,7 years, male sex in 63%, Caucasian ethnicity in 90%, smoking history in 86%, good performance status (0-1) 89% and stage IIIA and IIIB in 52% and 48%, respectively. Thirty-eight (52%) patients had adenocarcinoma, 24 (34%) squamous cell and 10 (13%) other histologies. All patients were treated with EP concurrent to radiation and 20% received two consolidation cycles of chemotherapy. Fifty-three (72%) completed all the treatment and 34 (45%) achieved complete or partial response. In the observational period 64 patients (88%) had died, with progression free survival of 10,1 months (95% IC, 6.97 to 13.17) and overall survival of 15.9 months (95% IC, 9.83 to 22.10). In multivariable analysis, clinical stage (IIIA vs IIIB) and performance status (0-1 vs ≥ 2) were independently associated with survival, HR 2.23 (95% IC, 1.16 to 4.29) and HR 6.39 (95% IC, 2.09 to 19.54), respectively.
Conclusion:
To our knowledge, this is the first Brazilian report of concurrent chemoradiation of locally advanced non small cell lung patients. Our outcomes are similar to previously reported clinical trials of concurrent treatment. Stage IIIB and performance status > 2 were predictors of worst outcomes in our population.
